96,716 XNAS Volume
XNAS 14 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| N. David Eansor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Juan Vera | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 50,000 | 50,000 | - | - | Employee Stock Option (right to buy) | |
| Katharine Knobil | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| A. Elms Steven | Director | Purchase of securities on an exchange or from another person at price $ 3.20 per share. | 23 Dec 2024 | 11,085 | 325,370 (0%) | 0% | 3.2 | 35,472 | Common Stock |
| Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| John Wilson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Katharine Knobil | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Juan Vera | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Michael J. Loiacono | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2023 | 38,480 | 38,480 | - | - | Employee Stock Option (right to buy) | |
| Juan Vera | Director, Chief Scientific Officer & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2023 | 46,487 | 46,487 | - | - | Employee Stock Option (right to buy) | |
| Tsvetelina Pencheva Hoang | VP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2023 | 33,159 | 33,159 | - | - | Employee Stock Option (right to buy) | |
| Mythili Koneru | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2023 | 51,918 | 51,918 | - | - | Employee Stock Option (right to buy) | |
| Nadia Agopyan | SVP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2023 | 34,154 | 34,154 | - | - | Employee Stock Option (right to buy) | |
| Anna Szymanska | Vice President, Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2023 | 29,947 | 29,947 | - | - | Employee Stock Option (right to buy) | |
| N. David Eansor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| David Laskow-Pooley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| John Wilson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Katharine Knobil | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Peter L. Hoang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2022 | 199,094 | 531,662 (1%) | 0% | 0 | Common Stock | |
| Peter L. Hoang | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.48 per share. | 24 Mar 2022 | 48,376 | 483,286 (1%) | 0% | 0.5 | 23,453 | Common Stock |
| Juan Vera | Director, Chief Scientific Officer & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.48 per share. | 24 Mar 2022 | 33,465 | 2,671,845 (5%) | 0% | 0.5 | 16,224 | Common Stock |
| Juan Vera | Director, Chief Scientific Officer & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2022 | 140,823 | 2,705,310 (5%) | 0% | 0 | Common Stock | |
| Anthony H. Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2022 | 150,512 | 150,512 (0%) | 0% | 0 | Common Stock | |
| Anthony H. Kim | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.48 per share. | 24 Mar 2022 | 36,076 | 114,436 (0%) | 0% | 0.5 | 17,490 | Common Stock |
| Michael J. Loiacono | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 140,000 | 140,000 | - | - | Employee Stock Option (right to buy) | |
| Peter L. Hoang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 430,000 | 430,000 | - | - | Employee Stock Option (right to buy) | |
| Juan Vera | Director, Chief Scientific Officer & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 160,000 | 160,000 | - | - | Employee Stock Option (right to buy) | |
| Tsvetelina Pencheva Hoang | VP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) | |
| Anthony H. Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 160,000 | 160,000 | - | - | Employee Stock Option (right to buy) | |
| Mythili Koneru | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 160,000 | 160,000 | - | - | Employee Stock Option (right to buy) | |
| Nadia Agopyan | VP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) | |
| Anna Szymanska | Vice President, Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) | |
| Gerald Garrett | Vice President, Clinical Ops. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) | |
| Katharine Knobil | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2021 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Frederick G. Wasserman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 12,658 | 65,223 (0%) | 0% | 0 | Common Stock | |
| N. David Eansor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 12,658 | 36,940 (0%) | 0% | 0 | Common Stock | |
| Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 12,658 | 29,680 (0%) | 0% | 0 | Common Stock | |
| David Laskow-Pooley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 12,658 | 55,223 (0%) | 0% | 0 | Common Stock | |
| John Wilson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 12,658 | 7,812,008 (16%) | 0% | 0 | Common Stock | |
| Frederick G. Wasserman | Director | Purchase of securities on an exchange or from another person at price $ 2.41 per share. | 18 May 2021 | 10,000 | 52,565 (0%) | 0% | 2.4 | 24,098 | Common Stock |
| Anthony A. Florence | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 16 Mar 2021 | 5,714,285 | 10,714,285 (23%) | 12% | 1.8 | 9,999,999 | Common Stock |
| N. David Eansor | Director | Purchase of securities on an exchange or from another person at price $ 17.50 per share. | 16 Mar 2021 | 14,285 | 16,713 (0%) | 0% | 17.5 | 249,988 | Common Stock |
| N. David Eansor | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Mar 2021 | 14,285 | 2,428 (0%) | 0% | 0 | Common Stock | |
| N. David Eansor | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Mar 2021 | 7,142 | 7,142 (0%) | 0% | 0 | Common Stock | |
| N. David Eansor | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Mar 2021 | 7,142 | 7,142 (0%) | 0% | 0 | Common Stock | |
| N. David Eansor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2021 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Sandell D Scott | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 16 Mar 2021 | 5,714,285 | 10,714,285 (23%) | 12% | 1.8 | 9,999,999 | Common Stock |
| Forest Baskett | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 16 Mar 2021 | 5,714,285 | 10,714,285 (23%) | 12% | 1.8 | 9,999,999 | Common Stock |
| Joshua Makower | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 16 Mar 2021 | 5,714,285 | 10,714,285 (23%) | 12% | 1.8 | 9,999,999 | Common Stock |
| Steven A. Elms | Director | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 16 Mar 2021 | 1,142,857 | 3,142,857 (6%) | 2% | 1.8 | 2,000,000 | Common Stock |
| Paul Walker | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 16 Mar 2021 | 5,714,285 | 10,714,285 (23%) | 12% | 1.8 | 9,999,999 | Common Stock |
| Ali Behbahani | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 16 Mar 2021 | 5,714,285 | 10,714,285 (23%) | 12% | 1.8 | 9,999,999 | Common Stock |
| Peter L. Hoang | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 16 Mar 2021 | 142,857 | 332,568 (0%) | 0% | 1.8 | 250,000 | Common Stock |
| Peter Sonsini | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 16 Mar 2021 | 5,714,285 | 10,714,285 (23%) | 12% | 1.8 | 9,999,999 | Common Stock |
| Carmen Chang | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 16 Mar 2021 | 5,714,285 | 10,714,285 (23%) | 12% | 1.8 | 9,999,999 | Common Stock |
| John Wilson | Director | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 16 Mar 2021 | 1,714,285 | 7,799,350 (16%) | 3% | 1.8 | 2,999,999 | Common Stock |
| Juan Vera | Chief Development Officer | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 16 Mar 2021 | 571,428 | 2,564,487 (5%) | 1% | 1.8 | 999,999 | Common Stock |
| Peter L. Hoang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 430,000 | 430,000 | - | - | Employee Stock Option (right to buy) | |
| Michael J. Loiacono | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 140,000 | 140,000 | - | - | Employee Stock Option (right to buy) | |
| Juan Vera | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 140,000 | 140,000 | - | - | Employee Stock Option (right to buy) | |
| Tsvetelina Pencheva Hoang | VP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) | |
| Anthony H. Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 160,000 | 160,000 | - | - | Employee Stock Option (right to buy) | |
| Mythili Koneru | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 140,000 | 140,000 | - | - | Employee Stock Option (right to buy) | |
| Nadia Agopyan | VP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) | |
| Anna Szymanska | Vice President, Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) | |
| Gerald Garrett | Vice President, Clinical Ops. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) | |
| Michael J. Loiacono | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 119,100 | 119,100 | - | - | Employee Stock Option (Right to Buy) | |
| Michael J. Loiacono | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 20,900 | 20,900 | - | - | Employee Stock Option (Right to Buy) | |
| Peter L. Hoang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 41,200 | 41,200 | - | - | Employee Stock Option (Right to Buy) | |
| Peter L. Hoang | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 388,800 | 388,800 | - | - | Employee Stock Option (Right to Buy) | |
| Juan Vera | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 113,400 | 113,400 | - | - | Employee Stock Option (Right to Buy) | |
| Juan Vera | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 26,600 | 26,600 | - | - | Employee Stock Option (Right to Buy) | |
| Tsvetelina Pencheva Hoang | VP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 25,400 | 25,400 | - | - | Employee Stock Option (Right to Buy) | |
| Tsvetelina Pencheva Hoang | VP, Research and Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 14,600 | 14,600 | - | - | Employee Stock Option (Right to Buy) | |
| Anthony H. Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 32,500 | 32,500 | - | - | Employee Stock Option (Right to Buy) | |
| Anthony H. Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 127,500 | 127,500 | - | - | Employee Stock Option (Right to Buy) | |
| Mythili Koneru | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 116,100 | 116,100 | - | - | Employee Stock Option (Right to Buy) | |
| Mythili Koneru | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 23,900 | 23,900 | - | - | Employee Stock Option (Right to Buy) | |
| Nadia Agopyan | VP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 7,300 | 7,300 | - | - | Employee Stock Option (Right to Buy) | |
| Nadia Agopyan | VP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 32,700 | 32,700 | - | - | Employee Stock Option (Right to Buy) | |
| Anna Szymanska | Vice President, Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 32,500 | 32,500 | - | - | Employee Stock Option (Right to Buy) | |
| Anna Szymanska | Vice President, Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 7,500 | 7,500 | - | - | Employee Stock Option (Right to Buy) | |
| Gerald Garrett | Vice President, Clinical Ops. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 38,300 | 38,300 | - | - | Employee Stock Option (Right to Buy) | |
| Gerald Garrett | Vice President, Clinical Ops. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 1,700 | 1,700 | - | - | Employee Stock Option (Right to Buy) | |
| Nadia Agopyan | VP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2019 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | |
| Peter L. Hoang | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 4.62 per share. | 14 Aug 2019 | 10,000 | 189,711 (0%) | 0% | 4.6 | 46,200 | Common Stock |
| Steven A. Elms | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2019 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Frederick G. Wasserman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2019 | 7,260 | 25,543 (0%) | 0% | 0 | Common Stock | |
| David Eansor | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2019 | 7,260 | 7,260 (0%) | 0% | 0 | Common Stock | |
| David Laskow-Pooley | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2019 | 7,260 | 25,543 (0%) | 0% | 0 | Common Stock | |
| John Wilson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2019 | 7,260 | 6,068,043 (13%) | 0% | 0 | Common Stock | |
| Anthony H. Kim | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2018 | 400,000 | 400,000 | - | - | Employee Stock Option (Right to Buy) | |
| Michael J. Loiacono | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Oct 2018 | 300,000 | 300,000 | - | - | Employee Stock Option (Right to Buy) | |
| Peter L. Hoang | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Oct 2018 | 200,000 | 200,000 | - | - | Employee Stock Option (Right to Buy) | |
| Peter L. Hoang | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Oct 2018 | 1,359,855 | 1,359,855 | - | - | Employee Stock Option (Right to Buy) | |
| Juan Vera | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Oct 2018 | 500,000 | 500,000 | - | - | Employee Stock Option (Right to Buy) | |
| David Eansor | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Oct 2018 | 12,500 | 12,500 | - | - | Non-Employee Director Stock Option (Right to Buy) | |
| John Wilson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Oct 2018 | 12,500 | 12,500 | - | - | Non-Employee Director Stock Option (Right to Buy) | |
| Frederick G. Wasserman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2018 | 5,168 | 18,283 (0%) | 0% | 0 | Common Stock | |
| Mark Reddish | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2018 | 4,106 | 36,110 (0%) | 0% | 0 | Common Stock | |
| Sherry Grisewood | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2018 | 4,106 | 19,582 (0%) | 0% | 0 | Common Stock | |
| Joshua Nathaniel Silverman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2018 | 4,106 | 17,221 (0%) | 0% | 0 | Common Stock | |
| David Laskow-Pooley | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2018 | 5,168 | 18,283 (0%) | 0% | 0 | Common Stock | |
| Glynn Wilson | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 09 Oct 2018 | 7,561 | 181,776 (1%) | 0% | 0 | Common Stock | |
| Glynn Wilson | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Oct 2018 | 31,120 | 0 | - | - | Employee Employment Agreement (right to receive) | |
| Glynn Wilson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2018 | 31,120 | 189,337 (1%) | 0% | 0 | Common Stock | |
| Glynn Wilson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2018 | 31,120 | 31,120 | - | - | Common Stock | |
| Joshua Nathaniel Silverman | None | Other type of transaction at price $ 0.00 per share. | 28 Feb 2018 | 41,667 | 41,667 | - | - | Series D Warrants | |
| Joshua Nathaniel Silverman | None | Other type of transaction at price $ 0.00 per share. | 28 Feb 2018 | 44,000 | 44,000 | - | - | Series C Warrants | |
| Joshua Nathaniel Silverman | None | Other type of transaction at price $ 0.00 per share. | 28 Feb 2018 | 41,667 | 41,667 | - | - | Series A Warrants | |
| Joshua Nathaniel Silverman | None | Other type of transaction at price $ 0.00 per share. | 28 Feb 2018 | 153,333 | 153,333 (1%) | 1% | 0 | Common Stock | |
| Joshua Nathaniel Silverman | None | Other type of transaction at price $ 0.00 per share. | 28 Feb 2018 | 49,167 | 49,167 | - | - | Series F Warrants | |
| Joshua Nathaniel Silverman | None | Other type of transaction at price $ 0.00 per share. | 28 Feb 2018 | 31,093 | 31,093 | - | - | Series E-1 Warrants | |
| Joshua Nathaniel Silverman | None | Other type of transaction at price $ 0.00 per share. | 28 Feb 2018 | 10,574 | 10,574 | - | - | Series E Warrants | |
| Glynn Wilson | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.18 per share. | 22 Sep 2017 | 27,350 | 158,217 (1%) | 0% | 3.2 | 86,973 | Common Stock |
| Glynn Wilson | None | Grant, award, or other acquisition of securities at price $ 3.18 per share. | 22 Sep 2017 | 100,000 | 185,567 (1%) | 0% | 3.2 | 318,000 | Common Stock |
| Peter L. Hoang | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 3.18 per share. | 22 Sep 2017 | 250,000 | 250,000 (2%) | 2% | 3.2 | 795,000 | Common Stock |
| Peter L. Hoang | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.18 per share. | 22 Sep 2017 | 70,289 | 179,711 (1%) | 0% | 3.2 | 223,519 | Common Stock |
| Frederick G. Wasserman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2017 | 13,115 | 13,115 (0%) | 0% | 0 | Common Stock | |
| Mark Reddish | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2017 | 13,115 | 32,004 (0%) | 0% | 0 | Common Stock | |
| Sherry Grisewood | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2017 | 13,115 | 15,476 (0%) | 0% | 0 | Common Stock | |
| Joshua Nathaniel Silverman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2017 | 13,115 | 13,115 (0%) | 0% | 0 | Common Stock | |
| David Laskow-Pooley | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2017 | 13,115 | 13,115 (0%) | 0% | 0 | Common Stock | |
| John N. Bonfiglio | Director, President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2017 | 5,220 | 26,054 (0%) | 0% | 0 | Common Stock | |
| Glynn Wilson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2017 | 12,761 | 85,567 (1%) | 0% | 0 | Common Stock | |
| John N. Bonfiglio | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2016 | 10,417 | 31,251 | - | - | Common Stock | |
| John N. Bonfiglio | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2016 | 10,417 | 85,416 | - | - | Employee Stock Option (Right to Buy) | |
| John N. Bonfiglio | Director, President and COO | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Dec 2016 | 10,417 | 20,834 | - | - | Common Stock | |
| John N. Bonfiglio | Director, President and COO | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Dec 2016 | 10,417 | 10,417 | - | - | Common Stock | |
| Joshua Silverman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Nov 2016 | 12,500 | 12,500 | - | - | Employee Stock Option (Right to Buy) | |
| Glynn Wilson | Director, CEO | Other type of transaction at price $ 0.00 per share. | 17 Feb 2012 | 166,667 | 1,213,726 | - | - | Common Stock | |
| Denis Corin | Director, President | Other type of transaction at price $ 0.00 per share. | 17 Feb 2012 | 166,667 | 2,394,535 | - | - | Common Stock | |
| Glynn Wilson | Director, Chairman and CEO | Other type of transaction at price $ 0.00 per share. | 23 Mar 2011 | 147,059 | 1,047,059 | - | - | Common Stock | |
| Denis Corin | Director, President and CFO | Other type of transaction at price $ 0.00 per share. | 23 Mar 2011 | 294,118 | 2,227,868 | - | - | Common Stock | |
| Denis Corin | Director, President and CFO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 23 Mar 2011 | 160,000 | 135,300 | - | - | Common Stock | |
| Tracy A. Moore | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Oct 2009 | 500,000 | 500,000 | - | - | Stock Options | |
| Glynn Wilson | Director, Executive Chairman | Other type of transaction at price $ 0.00 per share. | 29 Jun 2009 | 900,000 | 900,000 | - | - | Common stock | |
| Glynn Wilson | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2009 | 1,600,000 | 1,640,000 | - | - | Stock Options | |
| Alan P. Lindsay | None | Other type of transaction at price $ 0.00 per share. | 11 Mar 2009 | 162,000 | 162,000 | - | - | Purchase Warrants | |
| Denis Corin | President and CEO | Other type of transaction at price $ 0.00 per share. | 11 Mar 2009 | 200,000 | 350,000 | - | - | Purchase Warrants | |
| Denis Corin | President and CEO | Other type of transaction at price $ 0.00 per share. | 11 Mar 2009 | 150,000 | 150,000 | - | - | Purchase Warrants | |
| Denis Corin | Director, President | Other type of transaction at price $ 0.00 per share. | 04 Feb 2009 | 295,300 | 295,300 | - | - | Common stock | |
| Denis Corin | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2009 | 14,458 | 54,458 | - | - | Purchase Warrants | |
| Denis Corin | Director, President | Other type of transaction at price $ 0.00 per share. | 04 Feb 2009 | 1,925,750 | 1,933,750 | - | - | Common stock | |
| Denis Corin | Director, President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2009 | 1,100,000 | 1,180,000 | - | - | Stock Options | |
| Denis Corin | President and CEO | Other type of transaction at price $ 0.00 per share. | 30 Jun 2008 | 1,000,000 | 800,000 | - | - | Option to buy | |
| Denis Corin | President and CEO | Other type of transaction at price $ 0.00 per share. | 24 Jun 2008 | 1,000,000 | 1,800,000 | - | - | Option to buy | |
| Wilfred Jefferies | Director, Chief Scientist Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2003 | 1,500,000 | 1,500,000 | - | - | Stock Options | |
| Ronald L. Handford | Director, President/CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2003 | 200,000 | 200,000 | - | - | Stock Options | |
| Grant Atkins | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2003 | 250,000 | 250,000 | - | - | Stock Options | |
| Wilfred Jefferies | Director, Chief Scientist Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2003 | 1,500,000 | 1,500,000 | - | - | Stock Options | |
| Ronald L. Handford | Director, President/CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2003 | 200,000 | 200,000 | - | - | Stock Options | |
| Grant Atkins | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2003 | 250,000 | 250,000 | - | - | Stock Options |